Four-Year Efficacy and Safety Data of Ustekinumab Use in Ulcerative Colitis

David P. Hudesman, MD, provides insight on approaching induction therapy and maintenance therapy for patients with relapsing ulcerative colitis.

David P. Hudesman, MD, reviews data presented at the ACG 2022 Annual Scientific Meeting on the safety and efficacy of ustekinumab for ulcerative colitis treatment.

David P. Hudesman, MD, reviews long-term extension study data for the corticosteroid-sparing effects of ustekinumab on ulcerative colitis as presented at ACG 2022.

David P. Hudesman, MD, discusses clinical implications from ACG 2022 data on ustekinumab therapy for the management of ulcerative colitis and shares advice for managing patients with the disease.